SAN DIEGO – Data from year 2 of the CENTAUR study demonstrated that cenicriviroc, or CVC, reduced certain biomarkers associated with fibrosis progression compared with placebo, according to findings presented at Digestive Disease Week.
These results build on findings from year 1 of the CENTAUR study that highlighted characteristics of patients with non-alcoholic steatohepatitis who are more likely to experience progression of fibrosis.
“CVC is an oral C-C chemokine receptor type 2/5 antagonist currently being evaluated for the treatment of liver fibrosis in adults with NASH,”

Source link